Jeremy Hengst, PhD

    • 397 Citations
    • 13 h-Index
    20022017
    If you made any changes in Pure, your changes will be visible here soon.

    Personal profile

    Research interests

    Dr. Jeremy Hengst's research focuses on the development of small-molecule sphingosine kinase inhibitors and the role of sphingosine kinase in development/progression of tobacco-carcinogen-induced lung cancer.

    The primary research interest of his laboratory is the identification of mechanisms involved in the oncogenic role of sphingosine kinase (SK). In cancer cells, dysregulation of cell growth and/or apoptosis is closely linked to the sphingolipid metabolites ceramide and sphingosine-l-phosphate (S-1-P). Ceramide induces cell growth arrest and apoptosis, whereas S-1-P, a further metabolite of ceramide, promotes cell growth and/or protects from apoptosis.

    Ample evidence indicates that S-1-P, formed by activation of SK, can serve as an intracellular second messenger that modulates signaling pathways critical for cancer cell growth and survival. In fact, S-1-P antagonizes apoptosis mediated by ceramide, a stress-induced sphingolipid metabolite, suggesting that the intracellular ratio of these two sphingolipid metabolites and consequent regulation of opposing signaling pathways are important factors that determine the fate of cancer cells.

    Hengst's lab hypothesizes that SK, which catalyzes formation of S-1-P, plays a pivotal role in regulation of cancer cell proliferation and/or survival. Currently, the lab is developing/optimizing small-molecule inhibitors of SK as anti-cancer therapeutic agents. Additionally, they are exploring the role of SK in the development and/or progression of lung cancer caused by carcinogens present in tobacco smoke.

    Understanding the role of SK in this process will allow Dr. Hengst's lab to validate its novel small-molecule SK inhibitors as potential anti-lung cancer therapeutic agents.

    Fingerprint Dive into the research topics where Jeremy Hengst is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

    • 3 Similar Profiles
    Tiopronin Chemical Compounds
    meprin A Medicine & Life Sciences
    Sphingolipids Medicine & Life Sciences
    Cells Chemical Compounds
    Metalloproteases Medicine & Life Sciences
    Neoplasms Medicine & Life Sciences
    Phosphotransferases Medicine & Life Sciences
    Cell Movement Medicine & Life Sciences

    Network Recent external collaboration on country level. Dive into details by clicking on the dots.

    Research Output 2002 2017

    • 397 Citations
    • 13 h-Index
    • 19 Article
    • 2 Chapter
    • 1 Short survey
    • 1 Review article

    SKI-178: A multitargeted inhibitor of sphingosine kinase and microtubule dynamics demonstrating therapeutic efficacy in acute myeloid leukemia models

    Hengst, J., Dick, T. E., Sharma, A., Doi, K., Hegde, S., Tan, S. F., Geffert, L., Fox, T. E., Sharma, A. K., Desai, D., Amin, S., Kester, M., Loughran, T. P., Paulson, R., Claxton, D., Wang, H-G. & Yun, J., 2017, In : Cancer Translational Medicine. 3, 4, p. 109-121

    Research output: Contribution to journalArticle

    11 Citations (Scopus)

    Sphingosine kinase inhibitors decrease viability and induce cell death in natural killer-large granular lymphocyte leukemia

    LeBlanc, F. R., Liu, X., Hengst, J., Fox, T., Calvert, V., Petricoin, E. F., Yun, J., Feith, D. J. & Loughran, T. P., Dec 2 2015, In : Cancer Biology and Therapy. 16, 12, p. 1830-1840 11 p.

    Research output: Contribution to journalArticle

    Large Granular Lymphocytic Leukemia
    Cell Death
    Sphingolipids
    G2 Phase Cell Cycle Checkpoints
    Apoptosis
    17 Citations (Scopus)

    The apoptotic mechanism of action of the sphingosine kinase 1 selective inhibitor SKI-178 in human acute myeloid leukemia cell lines

    Dick, T. E., Hengst, J., Fox, T. E., Colledge, A. L., Kale, V. P., Sung, S., Sharma, A., Amin, S., Loughran, T. P., Kester, M., Wang, H-G. & Yun, J., Mar 1 2015, In : Journal of Pharmacology and Experimental Therapeutics. 352, 3, p. 494-508 15 p.

    Research output: Contribution to journalArticle

    Myeloid Cells
    Acute Myeloid Leukemia
    Cell Line
    CDC2 Protein Kinase
    Cyclin-Dependent Kinases
    14 Citations (Scopus)

    The regulatory roles of ROCK and MRCK kinases in the plasticity of cancer cell migration

    Kale, V. P., Hengst, J., Desai, D., Amin, S. & Yun, J., Jun 1 2015, In : Cancer Letters. 361, 2, p. 185-196 12 p.

    Research output: Contribution to journalShort survey

    Cell Movement
    Phosphotransferases
    Neoplasms
    Signal Transduction
    Therapeutics
    8 Citations (Scopus)

    A novel selective multikinase inhibitor of ROCK and MRCK effectively blocks cancer cell migration and invasion

    Kale, V. P., Hengst, J., Desai, D., Dick, T. E., Choe, K. N., Colledge, A. L., Takahashi, Y., Sung, S., Amin, S. & Yun, J., Nov 28 2014, In : Cancer Letters. 354, 2, p. 299-310 12 p.

    Research output: Contribution to journalArticle

    Myotonic Dystrophy
    Cell Movement
    Phosphotransferases
    Neoplasms
    rho-Associated Kinases